Dr. Samuel Sanchez Rivera, MD
Dermatology (Dermatology Physician)
200 Grand Boulevard Los Prados, Plaza Los Prados Suite Z-5
Caguas, PR 00727
- Medicare participating
At a glance
- Medical school
- University of Puerto Rico School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 30
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Puerto Rico School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
PR license 15120
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 30
- Services billed
- 76
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in Caguas, PR | 536 |
| Betamethasone Valerate Other prescribers in Caguas, PR | 295 |
| Ciclopirox Other prescribers in Caguas, PR | 218 |
| Ciclopirox (ciclopirox olamine) | 179 |
| Triamcinolone Acetonide Other prescribers in Caguas, PR | 136 |
| Betamethasone Diprop Augmented (betamethasone/propylene glyc) | 120 |
| Desonide | 99 |
| Metronidazole Other prescribers in Caguas, PR | 80 |
| Clobetasol Propionate Other prescribers in Caguas, PR | 64 |
| Hydrocortisone Other prescribers in Caguas, PR | 47 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 11 payments worth $418 in total to this clinician.
| AbbVie Inc. | $209 |
|---|---|
| Eli Lilly Export S.a. Puerto Rico Branch | $101 |
| Genzyme Corporation | $83.17 |
| Pbg Puerto Rico LLC | $25.00 |
| Food and Beverage | $418 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 3 companies. The companies reported $363,524 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AbbVie Inc. · Active, not recruiting · NCT05889182 - A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum…
AbbVie Inc. - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie Inc. · Recruiting · NCT06012240 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
AbbVie Inc. · Active, not recruiting · NCT06118411 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
AbbVie Inc. · Active, not recruiting · NCT06389136 - [Trial of device that is not approved or cleared by the U.S. FDA]
AbbVie Inc. · Withheld · NCT07215247 - A phase 4, multicenter, open-label, single-arm study to investigate the efficacy of lebrikizumab in adult and adolescent participants with atopic dermatitis with limited body surface area involvement and high itch bur…
Eli Lilly Export S.a. Puerto Rico Branch - M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)
AbbVie Inc. - M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)
AbbVie Inc. - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie Inc. · Active, not recruiting · NCT03568318
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.